Abdallah Geara, MD, is an Associate Professor of Clinical Medicine at the University of Pennsylvania.

Recent approval of 5 agents across distinct mechanistic pathways has redefined the 

treatment landscape, therapeutic options no longer remain the limiting factor, but the earlier identification and risk stratification needed to deploy them effectively.

In a majority of patients first presenting with IgAN, 50% to 75% have already progressed to 

 stage 3, signaling the unmet need for earlier identification before eGFR falls below 60 mL/min/1.73m² and structural kidney damage becomes irreversible. This same threshold marks the point at which the therapeutic window for emerging targeted agents narrows, and the opportunity for meaningful nephron preservation diminishes.

HCPLive spoke with Abdallah Geara, MD, an Associate Professor of Clinical Medicine at the University of Pennsylvania, to delve deeper into the current clinical landscape for IgAN.

: IgA nephropathy is often called a silent disease in its early stages, but are there subtle signs that clinicians might be overlooking, and what early clinical clues should prompt a closer look?

From the physician’s perspective, patients may not have many symptoms, if any. Hematuria is a big one; a young patient with hematuria is usually sent to urology for initial evaluation, which could be appropriate in some cases, but in the majority of young patients with hematuria, a nephrology pathology is responsible, IgA nephropathy, or membranous disease. So if a urology evaluation is negative, a nephrology evaluation would be an appropriate next step.

: Delayed diagnosis remains a challenge in IgAN. Where does the diagnostic process tend to break down, and what practical steps can help clinicians recognize and refer patients sooner?

The second question ties into the first; hematuria, with or without proteinuria, needs an explanation. If there is no good urological explanation, a nephrology evaluation might get us closer to a diagnosis. We know that 75% of patients with IgA nephropathy, when biopsied, already have established CKD stage 3 in the United States. Early diagnosis is something we still need to work on. We do not have any screening measures for IgA nephropathy, and urinalysis is not part of screening or health maintenance for the majority of patients. All of these steps, if implemented, can improve early diagnosis.

: Once IgAN is confirmed, how do you approach risk stratification? Which clinical features or biomarkers carry the most weight in shaping your management strategy?

When it comes to prognostication, we have to integrate clinical markers, serum creatinine, proteinuria, and hypertension with demographic markers, including age and ethnicity, and histologic markers. All three together allow you to create a risk assessment for the patient, and based on that risk assessment, you can decide what the next step of treatment should be. As therapy is evolving, the treatment algorithm has changed quite a bit over the last few years and continues to evolve.

 The treatment landscape has evolved significantly. Can you give an overview of the major therapeutic classes now available and what distinguishes them mechanistically?

The recently updated guidelines give a broad framework on how to treat IgA nephropathy, putting therapy into two big categories: therapy that addresses the chronic disease component, and therapy that addresses the inflammation caused by IgA nephropathy.

For the chronic disease component, we have RAAS blockade and SGLT2 inhibitors, as well as newer agents addressing the endothelin pathway, including sparsentan and atrasentan.

For the inflammatory or IgA-driven pathway, we have traditional therapies including corticosteroids, hydroxychloroquine, and newer, more targeted therapies including targeted-release formulations of budesonide, complement inhibitors like iptacopan, and, more recently, zigakibart, an anti-APRIL monoclonal antibody. Additional medications are expected to be approved to address this inflammatory component.

: How have you been deciding between newer targeted agents and traditional approaches? What about a patient's profile has been tipping the scale?

As we see more and more data, I'm more convinced that IgA nephropathy does require some level of IgA modulation. Using a complement blocker, targeted-release corticosteroid, MMF, or anti-APRIL will be required in the majority of patients. How to sequence these agents and which to start with is more based on the patient's profile and their tolerance. I try to shy away from corticosteroids, and all these other agents do carry some level of immune modulation that needs to be considered. Safety is very important when comparing these agents, as we do not have head-to-head comparisons. From an efficacy perspective, while proteinuria improvement is roughly similar across agents, there are also differences in eGFR slope that must be considered.

: Some therapies act on systemic immune pathways while others target mucosal immunity or downstream inflammation. How should clinicians think about these mechanistic distinctions when building a treatment strategy?

I do not have a unified treatment strategy as of now. I combine the immunosuppressive/modulator approach with the chronic disease approach. In general, the more targeted, the better. Even the more systemic approaches are relatively targeted; complement inhibitors and anti-APRIL therapy are directed at specific pathways, and clinical trials have shown these did not lead to many adverse effects, particularly around infections. Targeted release at the mucosal level might be ideal for someone at high risk of infection or corticosteroid side effects, though some systemic absorption does occur. This needs to be balanced against the more systemic immune modulation seen with complement inhibitors or anti-APRIL approaches.

: Looking ahead, where do you see the biggest gaps remaining in IgAN , whether in diagnosis, predicting disease course, or developing new therapies?

There is room for improvement across all of these areas. For diagnosis, we still rely on a kidney biopsy to confirm IgA nephropathy; we do not have a biomarker that helps with diagnosis, assesses response to treatment, or predicts long-term prognosis. For therapy, the newer treatments do offer improvement compared to where we were before, but we still need to understand how to use them, for how long, and what the clinical course will look like when therapies are combined or used sequentially. There is still a lot to figure out. The data we are generating is very exciting for both patients and physicians dealing with IgA nephropathy, but there is still a lot to learn.

Editor’s Note: Abdallah reports relevant disclosures with Amgen, GlaxoSmithKline, Novartis, and others.

Sharma I, Panta R. Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine. 

. Published online December 22, 2025. doi:

Caster DJ, Abner CW, Walker PD, et al. Clinicopathological Characteristics of Adult IgA Nephropathy in the United States. Published online June 1, 2023. doi:

https://doi.org/10.1016/j.ekir.2023.06.016

Articles

Five recently approved agents spanning distinct mechanistic pathways have expanded IgA nephropathy (IgAN) therapy, shifting the primary unmet need toward earlier detection and risk stratification. Many patients are first diagnosed after substantial progression, with 50%–75% already at CKD stage 3, where eGFR <60 mL/min/1.73 m² limits nephron preservation potential. Persistent hematuria, with or without proteinuria, warrants nephrology evaluation when urologic workup is unrevealing. Treatment increasingly integrates chronic kidney protection with targeted IgA-driven immunomodulation.

Geara breaks down the clinical framework for the modern era of IgA nephropathy. 


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Stratifying Risk, Optimizing Therapy in IgA Nephropathy, With Abdallah Geara, MD

Mark Taylor, MD, a consultant psychiatrist from The Edinburgh Practice and a professor in the school of medicine and dentistry at Griffith University.

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

New data suggest glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide, are associated with lower risks of anxiety and 

 This contradicts prior concerns raised by the US Food and Drug Administration (FDA) regarding a potential link between GLP-1 therapies and suicidal ideation.

The FDA could not find evidence of this association after an investigation.

“If I were a GP or a diabetologist in the States, I'd be seriously looking at the results [of] this study to inform my choices,” Mark Taylor, MD, a consultant psychiatrist from The Edinburgh Practice and a professor in the school of medicine and dentistry at Griffith University in Australia, told 

“It is quite a powerful result, albeit a correlative or associative result rather than a definitive causality result.”

The Swedish registry-based analysis included 95,490 individuals with depression or anxiety who were prescribed antidiabetic medications between 2009 and 2022.

 Using a within-individual design to minimize confounding, investigators compared periods of GLP-1 receptor agonist use with non-use in the same patients.

Semaglutide was associated with a 42% reduced risk of worsening mental illness (adjusted hazard ratio [aHR], 0.58; 95% CI, 0.51 – 0.65), while liraglutide showed a more modest benefit (aHR, 0.82; 95% CI, 0.76–0.89). No significant associations were observed for exenatide or dulaglutide.

Secondary outcomes further supported semaglutide’s potential psychiatric benefit, including reduced risks of worsening depression (aHR, 0.56), anxiety (aHR, 0.62), and substance use disorder (aHR, 0.53). At the class level, GLP-1 receptor agonists were also associated with a lower risk of self-harm (aHR, 0.56).

“Within the GLP [class], semaglutide comes out as a clear winner,” Taylor said.

Taylor emphasized that the observed benefits are likely multifactorial. While improved metabolic health may contribute, emerging evidence suggests potential direct central nervous system effects.

“There does appear to be a central effect to a brain effect, and we're not quite sure what the mechanism of that is,” he said.

Taylor said randomized controlled trials are needed to better understand the relationship between GLP-1s and psychiatric health, but they are expensive and difficult to organize. He said it would be helpful to compare Zepbound or Mounjaro to semaglutide or assess correlations on dose response.

“Is a higher dose of a GLP one going to be more effective or not? We don't know that yet,” Taylor said.

Taipale H, Taylor M, Markku Lähteenvuo, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Jari Tiihonen. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry. 2026;13(4):327-335. 

doi:https://doi.org/10.1016/S2215-0366(26)00014-3

Taylor, M. GLP-1s Linked to Reduced Anxiety, Suicidality, With Mark Taylor, MD. HCPLive. Published March 21, 2026. Accessed March 24, 2026. 

https://www.hcplive.com/view/glp-1-receptor-agonists-linked-reduced-anxiety-suicidality-mark-taylor-md

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. US Food & Drug Administration. Published January 13, 2026. Accessed March 20, 2026. 

https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type

Videos

National cohort study finds semaglutide tied to reduced depression, anxiety, and self-harm risk in patients with diabetes and comorbid mental illness.
 

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Therapeutic innovation in gastroenterology has accelerated over the past decade, reshaping how clinicians evaluate treatment response, define success, and identify unmet needs across inflammatory and metabolic diseases. As the armamentarium expands, so too does the complexity of decision-making in both inflammatory bowel disease (IBD) and broader digestive disorders. The question is no longer whether options exist, but how to deploy them effectively—and when to pivot.

Advancing Gastroenterology from the Frontlines of Patient Care

, a gastroenterologist specializing in inflammatory bowel diseases at 

, explains that early identification of suboptimal response remains grounded in careful clinical reassessment. In the absence of predictive biomarkers that reliably match individual patients to specific agents, clinicians must synthesize disease severity, distribution, comorbidities, and patient preferences. Clinical trial data provide practical benchmarks—particularly regarding expected timelines for response. Some therapies demonstrate benefit within weeks, whereas others may require months, informing when optimization or switching should be considered.

, noted that 2025 marked a banner year for guideline development across ulcerative colitis, metabolic liver disease, and gastrointestinal bleeding. Institutional leadership in translational research continues to bridge laboratory discovery and bedside application, reinforcing the importance of evidence-based adaptation as new mechanisms of action emerge.

McDonald anticipates that emerging therapies—including anti-fibrotic strategies in Crohn disease—may necessitate new monitoring paradigms. While core goals remain unchanged—symptom control, mucosal healing, and durable remission—success metrics may expand as clinicians begin treating disease phenotypes previously managed surgically.

Cohen highlighted additional clinical lessons from 2025, including the growing use of combination biologic strategies to overcome therapeutic ceilings and the expanding investigation of glucagon-like peptide-1–based agents beyond metabolic indications. Looking ahead, both physicians identified precision medicine and microbiome-directed interventions as critical areas for trial development. Cohen emphasized prevention as a particularly underexplored frontier, including efforts to identify microbiome alterations preceding overt disease.

Together, their perspectives underscore a shared priority: refining therapeutic sequencing, improving patient-specific targeting, and designing clinical trials that better anticipate real-world complexity while advancing measurable, durable outcomes in digestive disease care.

Discover how new IBD therapies, combo drugs, and microbiome research aim to predict response, prevent Crohn’s complications, and expand trial options.

Advancing Gastroenterology from the Frontlines of Patient Care 

Allergist-immunologist at Yale New Haven Hospital

Why De-Labeling NNAALs Should Be Routine Obstetrics Care, With Chang Su, MD

With maternal non-narcotic analgesic allergy labels significantly associated with eclampsia (aRR, 1.5; 95% CI, 1.06–2.12), preterm birth (aRR, 1.21; 95% CI, 1.14–1.28), NICU admission (aRR, 1.17; 95% CI, 1.10–1.25), and neonatal withdrawal syndrome (aRR, 1.51; 95% CI, 1.24–1.84) across a California birth cohort of 2,244,210 singleton livebirths, the case for integrating allergy de-labeling into routine obstetric care is compelling.

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, from February 27 to March 2, with Chang Su, MD, allergist-immunologist at Yale New Haven Hospital, who conducted the research during her time at University of California San Francisco, she situated the NNAAL findings within a broader de-labeling effort already underway in obstetrics. Her group has had significant success with beta-lactam allergy de-labeling in collaboration with OB and primary care colleagues — driven in part by prior data showing that penicillin allergy labels, like NNAALs, divert patients away from first-line therapy, in that case for Group B streptococcal infection around the time of delivery. Approximately 90% of patients with a beta-lactam allergy label do not have a true allergy on formal evaluation, with emerging data suggesting the true negative rate may be even higher. A similar dynamic appears to apply to NNAALs: one prior study found that approximately 85% of patients carrying such a label can ultimately tolerate NSAIDs, suggesting a substantial proportion of the 10,460 NNAAL-carrying mothers in the SABLE cohort may have been unnecessarily restricted from first-line analgesics and aspirin-based preeclampsia prevention.

Critically, Su emphasized that de-labeling is not an all-or-nothing proposition. For patients who cannot be fully cleared — due to the nature of their prior reaction — a formal allergy evaluation can still produce a concrete, individualized action plan specifying dose thresholds and tolerable agents. In the context of preeclampsia prevention, for example, a patient who cannot tolerate the recommended 162 mg aspirin dose may still safely receive 81 mg, a clinically meaningful alternative that would otherwise go unprescribed without specialist input. Su described ongoing efforts to expand this model beyond beta-lactams to other drug classes — including NNAALs — and stressed that the referral pipeline from OB-GYN colleagues is central to making de-labeling scalable as a component of routine prenatal care.

“For example, for preeclampsia prevention, aspirin 162 milligrams is often recommended. But for certain patients, perhaps they can tolerate 81 milligrams based on the types of reaction that they had. And if we can prove that, then perhaps we can't get them the most recommended therapy, but we can get the second best of them,” Su said.

Su has no relevant disclosures to report.

1. Su C, Baer R, Otani I, Schatz M, Chambers C. The relationship between maternal non-narcotic analgesics allergy labels and maternal and fetal outcomes: results from a large, administrative cohort. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #L24

2. Non-Narcotic Analgesics Allergy Labels Linked to Adverse Maternal and Fetal Outcomes. News release. AAAAI. February 26, 2026. 

https://www.aaaai.org/about/news/news/2026/narcotic

Su discussed the role of delabeling non-narcotic analgesic allergy labels in obstetrics care.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Mercedes Martinez, MD, is a professor of pediatrics and medicine, medical director of the intestinal transplant program at the Center for Liver Disease and Abdominal Organ Transplantation, and medical director of the pediatric abdominal organ transplantation program at NewYork-Presbyterian.

Expanding Maralixibat for Rare Cholestatic Liver Diseases: Cholestatic Pruritus Explained

For patients with rare cholestatic liver diseases, pruritus is a debilitating, often underrecognized symptom that can severely disrupt sleep, daily function, and quality of life. Frequently worsening at night and with heat or activity, it remains difficult to measure and does not reliably correlate with standard biomarkers like bile acids or bilirubin. As awareness grows and new therapies are being studied, there is increasing urgency to better recognize and more effectively treat this overlooked but life-altering burden.

, Mercedes Martinez, MD, a professor of pediatrics and medicine at CUMC, highlighted both the clinical burden of cholestatic pruritus and the growing promise of targeted therapies like maralixibat.

One of the central challenges, Martinez explained, is the lack of objective tools to quantify pruritus severity. Unlike laboratory markers such as bilirubin or bile acid levels, itch does not reliably correlate with measurable disease parameters. Some patients with markedly elevated bile acids report little to no pruritus, while others with only moderate elevations experience debilitating symptoms, a disconnect that can lead clinicians to underestimate the true burden of disease.

“That right there is a problem. We don't have an objective assessment of how much pruritus somebody can feel. It's a feeling, and because it's a feeling, sometimes people try to downplay it, and physicians don't recognize that this is a problem,” she explained. “Sometimes, when we don't understand something and we don't have an objective assessment or something, we try to downplay that.”

The consequences for patients, particularly children, can be profound. Martinez described cases of severe, relentless itching that disrupt sleep, limit physical activity, and significantly impair quality of life. In extreme instances, patients scratch to the point of bleeding or engage in harmful behaviors in an attempt to relieve symptoms. Pruritus is often worse at night, exacerbated by heat or physical exertion, and may go underreported because patients normalize the sensation over time. As a result, more proactive and specific questioning by clinicians is essential to fully capture symptom burden.

From a mechanistic standpoint, she says the role of bile acids is central. The body typically recycles approximately 95% of bile acids through reabsorption in the terminal ileum. In cholestatic disease, impaired bile acid handling contributes to symptom development.

Therapies that interrupt this recycling process can therefore help reduce pruritus. While older treatments such as bile acid sequestrants are poorly tolerated, newer ileal bile acid transporter (IBAT) inhibitors like maralixibat offer a more targeted approach by blocking bile acid reuptake and lowering systemic levels.

While it is already approved for conditions such as Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), where pruritus is a hallmark feature, Martinez noted that the underlying mechanism of cholestatic pruritus is shared across multiple liver diseases, suggesting broader therapeutic potential. In clinical practice, off-label use has shown benefit in conditions such as primary sclerosing cholangitis and biliary atresia, though access remains limited due to lack of formal approval.

She noted that this is where the ongoing EXPAND trial becomes critical. By evaluating maralixibat in a wider population of rare cholestatic liver diseases, the study aims to establish both efficacy and safety beyond its current indications. According to Martinez, expanding approval could alleviate not only the clinical burden of pruritus but also the financial and access barriers faced by families.

Ultimately, improving recognition of pruritus and broadening access to effective therapies may significantly transform care for patients living with these challenging conditions.

Editors’ Note: Martinez reports no relevant disclosures.

Brooks A. FDA Approves Maralixibat (Livmarli) Tablet for Alagille Syndrome, PFIC. HCPLive. April 14, 2025. Accessed March 24, 2026. 

https://www.hcplive.com/view/fda-approves-maralixibat-livmarli-tablet-alagille-syndrome-pfic

Mirum Pharmaceuticals. Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases. March 16, 2026. Accessed March 24, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Completes-Enrollment-in-Phase-3-EXPAND-Study-of-LIVMARLI-maralixibat-in-Additional-Rare-Cholestatic-Liver-Diseases/default.aspx

Martinez discusses unmet needs in pruritus management and maralixibat’s potential to expand treatment of itch across rare cholestatic liver diseases.

Hepatology

Expanding the Reach of Maralixibat in Rare Cholestatic Liver Diseases, With Mercedes Martinez, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

ACG's 24 new HE recommendations tackle ammonia testing, lactulose titration, protein intake, and transplant criteria for cirrhosis patients.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

ACG Issues New Hepatic Encephalopathy Guidelines For Diagnosis, Treatment, Nutrition, and Transplant, With Jasmohan Bajaj, MD, MS

Xiao Xiao, PhD, from the Behavioral and Cognitive Neuroscience Center at Fudan University.

Study reveals chronic pain reshapes hippocampus, driving depression risk. Microglia may be a therapeutic target, says Xiao.

Pain

The HCPLive pain page is a resource for medical news and expert insights on pain medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for acute pain, chronic pain, addiction medicine, and more.

Chronic Pain

On the HCPLive chronic pain page, resources on the topics of medical news and expert insight into pain treatment can be found. Content includes articles, interviews, videos, podcasts, and breaking news on chronic pain, and more.

Chronic Pain, Depression Linked Through Hippocampal Remodeling, With Xiao Xiao, PhD

Accelerated rTMS shows comparable efficacy to standard care, with delayed response in some patients and no clear predictors of early benefit.

Accelerated 5×5 rTMS Matches Standard Protocols in TRD, With Andrew Leuchter, MD

Podcasts

In this episode of the Skin of Color Savvy podcast, 2 leaders in dermatology discuss the complexities of colorism and its impact on pigmentary disorders.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Tackling Colorism in Dermatology, With Seemal Desai, MD, and Pearl Grimes, MD

Akl Fahed, MD, MPH, Interventional Cardiologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.

A metabolic polygenic risk score built from 20 traits and more than 8.5 million individuals outperformed existing disease-prediction models.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

When DNA Meets BMI: A New Way to Predict Metabolic Disease Earlier, With Akl Fahed, MD, MPH

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

ABCs in Dermatology: Previewing the 2026 AAD Annual Meeting

Hear Martha Gulati, MD, MS, reveal how mentorship and have shaped her career in women’s heart care.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Women's Health

On the HCPLive women's health page, resources on the topics of medical news and expert insight into obstetrics, gynecology, and women's related health can be found. Content includes articles, interviews, videos, podcasts, and breaking news on women's health, and more.

Moving the Needle in Medicine

Moving the Needle in Medicine is a monthly podcast from HCPLive Cardiology exploring the backstories and nuanced career paths that led the field’s movers and shakers to where they are today. Hosted by Alex Hajduczok, MD, the show will offer listeners insight into the biggest names in cardiology and beyond. 

This podcast is available via video on YouTube and on the HCPLive Cardiology podcast platforms on popular audio players.

Moving the Needle in Medicine: Blazing a Trail in Cardiology, with Martha Gulati, MD, MS

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This release by Apogee Therapeutics highlights findings from the phase 2 APEX trial on zumilokibart (APG777) in adults with moderate to severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

APEX: Zumilokibart Shows Durable Response at 52 Weeks in Atopic Dermatitis

David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.


Food Allergy

VIASKIN Peanut Patch Shows Strong Phase 3 VITESSE Results, With David Fleischer, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Phase 3b ENCORE shows inhaled ARIKAYCE boosts culture conversion and symptoms in antibiotic‑naïve MAC lung disease, paving way for 2026 label expansion.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Latest News

Stratifying Risk, Optimizing Therapy in IgA Nephropathy, With Abdallah Geara, MD

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

Advancing Gastroenterology from the Frontlines of Patient Care

Why De-Labeling NNAALs Should Be Routine Obstetrics Care, With Chang Su, MD

Expanding the Reach of Maralixibat in Rare Cholestatic Liver Diseases, With Mercedes Martinez, MD